反概率加权贝叶斯动态借用估计边际治疗效果及其在混合对照肿瘤研究中的应用。

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Matthew A Psioda, Nathan W Bean, Brielle A Wright, Yuelin Lu, Alejandro Mantero, Antara Majumdar
{"title":"反概率加权贝叶斯动态借用估计边际治疗效果及其在混合对照肿瘤研究中的应用。","authors":"Matthew A Psioda, Nathan W Bean, Brielle A Wright, Yuelin Lu, Alejandro Mantero, Antara Majumdar","doi":"10.1080/10543406.2025.2489285","DOIUrl":null,"url":null,"abstract":"<p><p>We propose an approach for constructing and evaluating the performance of inverse probability weighted robust mixture priors (IPW-RMP) which are applied to the parameters in treatment group-specific marginal models. Our framework allows practitioners to systematically study the robustness of Bayesian dynamic borrowing using the IPW-RMP to enhance the efficiency of inferences on marginal treatment effects (e.g. marginal risk difference) in a target study being planned. A key assumption motivating our work is that the data generation processes for the target study and external data source (e.g. historical study) will not be the same, likely having different distributions for key prognostic factors and possibly different outcome distributions even for individuals who have identical prognostic factors (e.g. different outcome model parameters). We demonstrate the approach using simulation studies based on both binary and time-to-event outcomes, and via a case study based on actual clinical trial data for a solid tumor cancer program. Our simulation results show that when the distribution of risk factors does in fact differ, the IPW-RMP provides improved performance compared to a standard RMP (e.g. increased power and reduced bias of the posterior mean point estimator) with essentially no loss of performance when the risk factor distributions do not differ. Thus, the IPW-RMP can safely be used in any situation where a standard RMP is appropriate.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-23"},"PeriodicalIF":1.2000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Inverse probability weighted Bayesian dynamic borrowing for estimation of marginal treatment effects with application to hybrid control arm oncology studies.\",\"authors\":\"Matthew A Psioda, Nathan W Bean, Brielle A Wright, Yuelin Lu, Alejandro Mantero, Antara Majumdar\",\"doi\":\"10.1080/10543406.2025.2489285\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We propose an approach for constructing and evaluating the performance of inverse probability weighted robust mixture priors (IPW-RMP) which are applied to the parameters in treatment group-specific marginal models. Our framework allows practitioners to systematically study the robustness of Bayesian dynamic borrowing using the IPW-RMP to enhance the efficiency of inferences on marginal treatment effects (e.g. marginal risk difference) in a target study being planned. A key assumption motivating our work is that the data generation processes for the target study and external data source (e.g. historical study) will not be the same, likely having different distributions for key prognostic factors and possibly different outcome distributions even for individuals who have identical prognostic factors (e.g. different outcome model parameters). We demonstrate the approach using simulation studies based on both binary and time-to-event outcomes, and via a case study based on actual clinical trial data for a solid tumor cancer program. Our simulation results show that when the distribution of risk factors does in fact differ, the IPW-RMP provides improved performance compared to a standard RMP (e.g. increased power and reduced bias of the posterior mean point estimator) with essentially no loss of performance when the risk factor distributions do not differ. Thus, the IPW-RMP can safely be used in any situation where a standard RMP is appropriate.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"1-23\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2025.2489285\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2489285","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

我们提出了一种构造和评估逆概率加权鲁棒混合先验(IPW-RMP)性能的方法,该方法应用于特定处理组边缘模型的参数。我们的框架允许从业者使用IPW-RMP系统地研究贝叶斯动态借用的鲁棒性,以提高正在计划的目标研究中对边际治疗效果(例如边际风险差异)的推断效率。激励我们工作的一个关键假设是,目标研究和外部数据源(例如历史研究)的数据生成过程将不相同,关键预后因素可能具有不同的分布,甚至对于具有相同预后因素的个体(例如不同的结果模型参数)也可能具有不同的结果分布。我们使用基于二进制和事件时间结果的模拟研究,并通过基于实体瘤癌症项目实际临床试验数据的案例研究来演示该方法。我们的模拟结果表明,当风险因素的分布确实不同时,与标准RMP相比,IPW-RMP提供了更好的性能(例如,增加了后验均值点估计器的功率和减少了偏差),而在风险因素分布不不同时基本上没有性能损失。因此,IPW-RMP可以安全地用于任何适合标准RMP的情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Inverse probability weighted Bayesian dynamic borrowing for estimation of marginal treatment effects with application to hybrid control arm oncology studies.

We propose an approach for constructing and evaluating the performance of inverse probability weighted robust mixture priors (IPW-RMP) which are applied to the parameters in treatment group-specific marginal models. Our framework allows practitioners to systematically study the robustness of Bayesian dynamic borrowing using the IPW-RMP to enhance the efficiency of inferences on marginal treatment effects (e.g. marginal risk difference) in a target study being planned. A key assumption motivating our work is that the data generation processes for the target study and external data source (e.g. historical study) will not be the same, likely having different distributions for key prognostic factors and possibly different outcome distributions even for individuals who have identical prognostic factors (e.g. different outcome model parameters). We demonstrate the approach using simulation studies based on both binary and time-to-event outcomes, and via a case study based on actual clinical trial data for a solid tumor cancer program. Our simulation results show that when the distribution of risk factors does in fact differ, the IPW-RMP provides improved performance compared to a standard RMP (e.g. increased power and reduced bias of the posterior mean point estimator) with essentially no loss of performance when the risk factor distributions do not differ. Thus, the IPW-RMP can safely be used in any situation where a standard RMP is appropriate.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信